Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: An international comparison (the GUESS Study)

Clinical Infectious Diseases

Volumn 41, Issue 1, 2005, Pages 92-99

  Zolopa, Andrew R ^a   Lazzeroni, Laura C ^a   Rinehart, Alex ^h   Vezinet, Françoise Brun ⁱ   Clavel, François ⁱ   Collier, Ann ^e   Conway, Brian ^k   Gulick, Roy M ^f   Holodniy, Mark ^a,b   Perno, Carlo Frederico ^l   Shafer, Robert W ^a   Richman, Douglas D ^c,d   Wainberg, Mark A ^j   Kuritzkes, Daniel R ^g  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h Virco BVBA   (Belgium)

ⁱ BICHAT HOSPITAL   (France)

^j MCGILL UNIVERSITY   (Canada)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^l UNIVERSITY OF ROME TOR VERGATA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANTI-HIV AGENTS; DATA INTERPRETATION, STATISTICAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INTERNATIONALITY; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 20844460472     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/430706     Document Type: Article

References (21)

1. Hirsch M, Brun-Vezinet F, Clotet, B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society -USA panel. Clin Infect Dis 2003; 37:113-28.
2. Yeni P, Hammer S, Hirsch M, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA panel. JAMA 2004; 292:251-65.
3. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at:http://www.aidsinfo.nih.gov/guidelines/. Accessed 2 May 2004.
4. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGuidelines Group for HIV Resistance. AIDS 2001; 15:309-20.
5. Shafer R, Jun D, Betts B. Human immunodeficiency virus type 1 reverse-transcriptase and protease mutation search engine for queries. Nat Med 2000; 6:1290-2.
6. Brun-Vezinet F, Descamps D, Ruffault A, et al. Clinically relevant interpretation of genotype for resistance to abacavir. The Narval (ANRS 088) Study group. AIDS 2003; 17:1795-802.
7. Schmidt B, Walter H, Zeitler N, Korn K. Genotypic drug resistance interpretation: the cutting edge of antiretroviral therapy systems. AIDS Rev 2002; 4:148-56.
8. Vandamme AM, Houyez F, Banhegyi D, et al. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antivir Ther 2001; 1:21-39.
9. Salama C, Policar M, Cervera C. Knowledge of genotypic resistance mutaions among providers of care to patients with human immunodeficiency virus. Clin Infect Dis 2003; 36:101-4.
10. Ravela J, Betts B, Brun-Vezinet F, et al. HIV-1 protease and reverse-transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. JAIDS 2003; 33: 8-14.
11. Kijak GH, Rubio AE, Pampuro SE, et al. Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms. HIV Med 2003; 4:72-8.
12. Puchhammer-Stockl E, Steininger C, Geringer E, Heinz FX. Comparison of virtual phenotype and HIV-SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains. HIV Med 2002; 3:200-6.
13. Walter H, Schmidt B, Werwein M, Schwingel E, Korn K. Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo. Antimicrob Agents Chemother 2002; 46:89-94.
14. Zazzi M, Romano L, Venturi G, et al. Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype. J Antimicrob Chemother 2004; 53:356-60.
15. De Luca A, Cingolani A, Di Giambenedetto S, et al. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 2003; 187:1934-43.
16. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. The Havana Study Group. AIDS 2002; 16:209-18.
17. Baxter J, Mayers D, Wentworth D, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. The CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). AIDS 2000; 14:F83-93.
18. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004; 189: 837-46.
19. Haubrich R, Keiser P, Kemper C, et al. Arandomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy: CCTG 575. AIDS 2005; 19:295-302.
20. Shulman N, Hughes M, Winters M, et al. Subtle changes in susceptibility to d4T predict virologic response to d4T monotherapy after AZT treatment. J AIDS 2002; 31:121-7.
21. Harrigan PR, Montaner JS, Wegner SA, et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001; 15:1671-7.